About Beijing Konruns Pharmaceutical Company

Adhering to the core mission of “using life science to care for human health”, the company has insisted on innovative drug research and development for 20 years, and has now developed into a high-tech pharmaceutical enterprise integrating R&D, production and marketing, and was listed on the Shanghai Stock Exchange in August 2018. Since its establishment, the company has been unswerving in the creation of new drugs: adhering to originality, highlighting new features, and pursuing excellence. The company currently has the national class 1 new drug, Sulin, which has already been marketed. In 2020, the company acquired Novartis original research drug Migasol Calcitonin injection and nasal spray, which enriched the company's product structure and provided the company with new profit growth points. It also has KC1036, ZY5301, and other national-class new drugs under development, and has received many top honors in China, such as the National 863 Program, the National Torch Program, and the China Patent Excellence Award. The company's industry is pharmaceutical manufacturing. The company focuses on hemostasis and perioperative period, tumor/immunity, bone metabolism, etc. The company's main products are the national first-class new drugs “Sulin” and “Mitigexin”. Corporate honors include: Beijing G20 Leading Enterprise, Beijing Enterprise Technology Center, National Torch Program, National Intellectual Property Demonstration Enterprise, National Postdoctoral Research Workstation, Beijing Engineering Laboratory's “Zhongguancun High-tech Enterprise Certificate”, successfully passed the Beijing Municipal Enterprise Science and Technology Research and Development Agency and Beijing's “Specialized and New” SME review, and was awarded “Top 100 Innovative Chinese Pharmaceutical Enterprises”, “Beijing Top 100 High-tech Enterprises”, “Beijing Top 100 High-tech Enterprises”, “Beijing Top 100 Professional and New Enterprises”, and “2023 China's Top 100 Biomedical Technology Innovation Value List” It won the “Top 10 Influential Biopharmaceutical Companies”, won the “8th Batch of National Manufacturing Individual Champion Enterprises by the Ministry of Industry and Information Technology”, and was selected as the “2023 Top 100 Chinese Chemical Companies List”.